EQS Group AG

EQS Group is a leading international technology provider for Investor Relations, Corporate Communications, and Corporate Compliance. More than 8,000 companies worldwide use EQS Group’s offerings to fulfill complex national and international disclosure obligations, to minimize risk, and to reach stakeholder.

EQS Group is a digital single-source provider for global teams. EQS Group’s products and services include a global newswire, regulatory news distribution, investor targeting and contact management, and insider list management. These are integrated within a cloud-based platform, the EQS COCKPIT, to streamline the workflows of Investor Relations, Communications, and Compliance professionals. The Group also offers an innovative whistleblowing and case management software, IR website services, digital reports, and webcasting solutions.

EQS Group was founded in 2000 in Munich, Germany. Today, the group employs over 400 professionals around the globe and has offices in the world’s key financial markets.

 PRESS RELEASE

EQS-News: Klassik Radio AG: Gemeinsame Stellungnahme des Vorstands und...

EQS-News: Klassik Radio AG / Schlagwort(e): Delisting Klassik Radio AG: Gemeinsame Stellungnahme des Vorstands und Aufsichtsrats zum öffentlichen Delisting-Erwerbsangebot der UK Media Invest GmbH veröffentlicht 21.11.2024 / 13:27 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Klassik Radio AG: Gemeinsame Stellungnahme des Vorstands und Aufsichtsrats zum öffentlichen Delisting-Erwerbsangebot der UK Media Invest GmbH veröffentlicht Augsburg, 21. November 2024 Die UK Media Invest GmbH mit Sitz in Augsburg, die als Mehrheitsanteils...

 PRESS RELEASE

NOTICE OF ANNUAL GENERAL MEETING

Grit Real Estate Income Group (GR1T) NOTICE OF ANNUAL GENERAL MEETING 21-Nov-2024 / 12:15 GMT/BST GRIT REAL ESTATE INCOME GROUP LIMITED (Registered in Guernsey) (Registration number: 68739) LSE share code: GR1T SEM share codes (dual currency trading): DEL.N0000 (USD) / DEL.C0000 (MUR) ISIN: GG00BMDHST63 LEI: 21380084LCGHJRS8CN05 ("Grit" or the "Company" or the "Group")       NOTICE OF ANNUAL GENERAL MEETING     Notice is hereby given to the shareholders of GRIT that the Annual General Meeting (“AGM”) will be held at 14h30 Mau...

 PRESS RELEASE

EQS-News: audius mit erfolgreichem dritten Quartal 2024 – Gesamtleistu...

EQS-News: audius SE / Schlagwort(e): 9-Monatszahlen audius mit erfolgreichem dritten Quartal 2024 – Gesamtleistung wächst um +9,2% und EBITDA um +14,6% 21.11.2024 / 12:35 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.   Gesamtleistung im dritten Quartal steigt um 9,2% auf 21,5 Mio. Euro (Vorjahr 19,7 Mio. Euro) EBITDA legt um 14,6% auf 2,1 Mio. Euro zu (Vorjahr 1,8 Mio. Euro) Wachstum der Gesamtleistung nach 9 Monaten um 6,2% auf 61,9 Mio. Euro (Vorjahr 58,3 Mio. Euro)  Weinstadt, 21.11.2024 Die audius Gruppe blickt zurück auf ein...

 PRESS RELEASE

EQS-News: audius with successful third quarter 2024 - total revenue gr...

EQS-News: audius SE / Key word(s): 9 Month figures audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6 21.11.2024 / 12:35 CET/CEST The issuer is solely responsible for the content of this announcement.   Total revenue increases by 9.2% to EUR 21.5 million in the third quarter (previous year: EUR 19.7 million) EBITDA increases by 14.6% to EUR 2.1 million (previous year EUR 1.8 million) Growth in total revenue after 9 months of 6.2% to EUR 61.9 million (previous year EUR 58.3 million) Weinstadt, 21.11.2024 The audius Group can loo...

 PRESS RELEASE

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Pro...

Hardman & Co Research Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven 21-Nov-2024 / 11:15 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven  Shield is a commercial-stage pharma company delivering specialty products that address the needs of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the diffe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch